Oct. 17, 2006
UI Medication Study Invites People With Schizophrenia
People ages 18 to 65 who have been diagnosed with schizophrenia or schizoaffective disorder are invited to participate in a study comparing newer medications at the University of Iowa Department of Psychiatry.
The study, which is funded by the National Institute of Mental Health, will evaluate the long-term effectiveness of long-acting, injectable risperidone compared to newer oral antipsychotic medication.
Interested participants must have experienced troublesome symptoms of illness within the past 12 months. Participants who are determined to be eligible will be asked to visit the study team at UI Hospitals and Clinics every two weeks for up to two-a-half years. The visits primarily will involve interviews, medication review, and blood pressure and other basic health checks. These visits will last from approximately 30 minutes to three hours.
Participants will be assigned to one of the two study treatment groups. Thus, each participant will have a 50 percent chance of receiving the long-acting, injectable risperidone and a 50 percent chance of receiving a newer oral antipsychotic. If assigned to oral medication, the participant and study physician will together determine which of the available medications is best for that individual.
There are no charges for any of the study procedures or medications. Compensation is available for participants' time and travel expenses.
The UI is one of eight sites nationwide participating in the study. Approximately 38 individuals will participate at the UI site, where the principal investigator is Del Miller, M.D., professor of psychiatry in the UI Roy J. and Lucille A. Carver College of Medicine.
For more information, contact Jane Kerr at 319-353-4955 or mailto:firstname.lastname@example.org or Tim Holman at 319-335-6769 or mailto:email@example.com.
Visit the Department of Psychiatry research Web site at http://www.uihealthcare.com/depts/med/psychiatry/healthprofessionals/research.html.
STORY SOURCE: University of Iowa Health Science Relations, 5137 Westlawn, Iowa City, Iowa 52242-1178
Interested Participants: UI Health Access toll free at 800-777-8442
Jane Kerr at 319-353-4955 or firstname.lastname@example.org
Tim Holman at 319-335-6769 or email@example.com
MEDIA CONTACT: Becky Soglin, 319 335-6660 firstname.lastname@example.org